This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Long-range epigenetic silencing at 2q14.2 affects most human colorectal cancers and may have application as a non-invasive biomarker of disease
British Journal of Cancer Open Access 21 April 2009
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Osborn NK and Ahlquist DA (2005) Stool screening for colorectal cancer: molecular approaches. Gastroenterology 128: 192–206
Tagore K et al. (2003) Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia. Clin Colorectal Cancer 3: 47–53
Ahlquist DA et al. (1993) Accuracy of fecal occult blood screening for colorectal neoplasia: a prospective study using Hemoccult and HemoQuant tests. JAMA 269: 1262–1267
Song K et al. (2004) Fecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis. Gastroenterology 126: 1270–1279
Acknowledgements
The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Glossary
- SENSITIVITY
-
The likelihood that a test is positive in the presence of disease
- TNM STAGE
-
Tumor-node-metastasis stage
- SPECIFICITY
-
The likelihood that a test is negative in the absence of disease
- FECAL MARKER
-
Any type of molecule leaked (i.e. hemoglobin), secreted or exfoliated (i.e. cells, DNA) that can be recovered, detected and analyzed in stools
Rights and permissions
About this article
Cite this article
Capellá, G. Is fecal DNA testing superior to fecal occult-blood testing for colorectal cancer screening?. Nat Rev Clin Oncol 2, 234–235 (2005). https://doi.org/10.1038/ncponc0170
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncponc0170